Population
Patients with nondystrophic myotonias (NDMs) and periodic paralyses
Design
Review
Authors
Loading...
No immediate change to management of hypokalaemic periodic paralysis; extends molecular insights but leaves open the need for RCTs to guide therapy.
Recent genetic and pathophysiological discoveries in skeletal muscle channelopathies highlight the need for randomized controlled trials to establish standard treatments.
Rayan et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: